Pre-earnings options volume in MannKind is normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 9.3%, or 35c, after results are released. Median move over the past eight quarters is 4.9%.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MNKD:
- MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
- MannKind completes enrollment in Phase 4 trial in diabetes
- MNKD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
- MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent